Cjc 1295 Dac Price
Evaluating the baseline CJC 1295 DAC price requires looking beyond surface-level milligram costs to assess analytical verification, batch purity, and manufacturing standards. This guide details the primary determinants of research peptide pricing, chemical characterization requirements, and quality validation metrics necessary for reproducible preclinical research.
Quick answer
Evaluating the baseline CJC 1295 DAC price requires looking beyond surface-level milligram costs to assess analytical verification, batch purity, and manufacturing standards. This guide details the primary determinants of research peptide pricing, chemical characterization requirements, and quality validation metrics necessary for reproducible preclinical research.
Key takeaways
- The market CJC 1295 DAC price for verified research-grade material typically ranges between $30 and $70 per 5mg vial, with unit costs scaling down significantly during bulk institutional procurement.
- [CJC-1295](/research-peptides/cjc-1295-no-dac) with Drug Affinity Complex (DAC) is a modified 29-amino-acid synthetic peptide derivative of growth hormone-releasing hormone (GHRH).
- As a potent GHRH receptor agonist, [CJC-1295](/research-peptides/cjc-1295-no-dac) DAC activates the growth hormone-releasing hormone receptor on pituitary somatotropes.
- Understanding CJC 1295 DAC price dynamics requires examining the multi-step Solid-Phase Peptide Synthesis (SPPS) process.
Direct Market Overview: CJC 1295 DAC Price Determinants
The market CJC 1295 DAC price for verified research-grade material typically ranges between $30 and $70 per 5mg vial, with unit costs scaling down significantly during bulk institutional procurement. Variations in unit price are driven primarily by synthesis quality, the rigors of third-party analytical testing, and the inclusion of lot-specific documentation such as high-performance liquid chromatography (HPLC) and mass spectrometry (MS) reports.
When procuring CJC-1295 DAC for laboratory applications, low baseline pricing often signals omitted analytical testing, unverified purity, or high levels of residual endotoxins. High-purity preparations synthesized under strict quality control standards require higher operational investment, ensuring that research laboratories receive stable, biologically active, and contaminant-free reagents.
Chemical Structure and the DAC™ Modification Mechanism
CJC-1295 with Drug Affinity Complex (DAC) is a modified 29-amino-acid synthetic peptide derivative of growth hormone-releasing hormone (GHRH). The base sequence, structurally optimized from native GHRH(1-29), incorporates D-alanine, glutamine, alanine, and leucine substitutions at positions 2, 8, 15, and 27 to resist rapid enzymatic cleavage by dipeptidyl peptidase IV (DPP-IV).
The critical structural differentiator of CJC-1295 DAC is the addition of a maleimidopropionic acid (MPA) linker reactive group bound to the Lys29 residue. Upon exposure to physiological or simulated biological fluids, this linker selectively forms a stable, covalent bond with the free Cys34 thiol group of endogenous serum albumin. In preclinical models, this bioconjugation extends the plasma elimination half-life from minutes to approximately 6–8 days, protecting the molecule from renal clearance and enzymatic degradation.
Preclinical Applications and Receptor Kinetics
As a potent GHRH receptor agonist, CJC-1295 DAC activates the growth hormone-releasing hormone receptor on pituitary somatotropes. This binding stimulates adenylate cyclase activity, elevating intracellular cyclic adenosine monophosphate (cAMP) levels and triggering signal transduction cascades that promote growth hormone (GH) transcription and release.
In preclinical studies, CJC-1295 DAC is studied as a long-acting growth-hormone-releasing hormone that sustains GH and downstream IGF-1 levels for tissue repair research. Unlike short-acting GHRH analogs that yield transient GH spikes, the prolonged half-life achieved through albumin binding results in a sustained, baseline elevation of GH and insulin-like growth factor 1 (IGF-1). Researchers utilize this altered secretagogue profile to model chronic GH receptor activation, extracellular matrix remodelling, and localized tissue regeneration kinetics in laboratory settings.
Cost Drivers in Research Peptide Synthesis
Understanding CJC 1295 DAC price dynamics requires examining the multi-step Solid-Phase Peptide Synthesis (SPPS) process. The synthesis of complex modified peptides involves costly protected amino acid precursors, specialized coupling reagents, and precise reaction cycles. The integration of the maleimide functional group demands meticulous handling during cleaving and purification to avoid unintended side reactions or ring-opening hydrolysis.
Following synthesis, crude peptide mixtures undergo preparative Reverse-Phase High-Performance Liquid Chromatography (RP-HPLC) to separate the target sequence from truncated sequences and deletion peptides. Generating a finished product that consistently exceeds 98% purity requires iterative purification steps, significantly increasing production overhead compared to raw, unpurified industrial runs.
Quality Verification: COA, HPLC, and Mass Spectrometry
To ensure experimental validity, researchers must evaluate supplier documentation rather than relying solely on catalog pricing. Every batch of research peptides supplied by PX1 Research undergoes rigorous testing in an independent, ISO 17025-accredited laboratory to confirm molecular identity and quantitative purity.
A valid Certificate of Analysis (COA) must provide dual-spectrum verification. RP-HPLC chromatograms establish purity percentages by measuring peak area integration, ensuring minimal structural impurities. Electrospray Ionization Mass Spectrometry (ESI-MS) confirms molecular weight, ensuring the target mass matches the theoretical value of 3647.95 Da for CJC-1295 DAC. Furthermore, Limulus Amebocyte Lysate (LAL) testing is critical to verify that endotoxin levels remain below stringent research thresholds (<0.01 EU/mg).
Comparative Analysis: CJC-1295 DAC vs. Short-Acting Secretagogues
When designing protocols, investigators frequently compare CJC-1295 DAC against shorter-acting secretagogues to evaluate pharmacokinetic variances. While CJC-1295 DAC offers an extended half-life through covalent albumin binding, non-DAC variants exhibit distinct pulse dynamics that suit different experimental setups.
For instance, CJC-1295 No DAC (also known as Mod GRF 1-29) provides a transient GH surge lasting approximately 30 minutes, allowing researchers to study physiological, pulsatile release profiles. When synergistic GHRH and GHRP signaling is required, researchers often pair Mod GRF with Ipamorelin or analyze historical benchmarks using Sermorelin. A detailed breakdown of these pharmacokinetic differences can be found in our technical article on CJC-1295 DAC vs No DAC.
Laboratory Reconstitution and Handling Protocols
Lyophilized CJC-1295 DAC must be stored under controlled conditions to maintain chemical stability. Upon receipt, unopened vials should be kept at -20°C or -80°C for long-term preservation. Prior to reconstitution, vials should be allowed to equilibrate to room temperature to prevent condensation within the matrix.
Reconstitution should be performed using sterile bacteriostatic water containing 0.9% benzyl alcohol as a preservative. The diluent should be introduced down the glass wall of the vial rather than sprayed directly onto the lyophilized cake. Gentle swirly motion should be used to facilitate dissolution; mechanical agitation, vigorous shaking, or sonication must be avoided to prevent peptide aggregation or cleavage of sensitive chemical linkers.
Storage, Thermal Stability, and Cold-Chain Logistics
The physical stability of synthetic peptides is heavily influenced by environmental exposure. Lyophilized CJC-1295 DAC exhibits relative stability during ambient transit, but reconstituted solutions require strict refrigeration at 2°C to 8°C and should be utilized within an established experimental window to limit hydrolytic degradation.
PX1 Research mitigates transit risk by dispatching orders directly from state-of-the-art facilities in California and Arizona. Utilizing same-day fulfillment (Monday–Friday) and protective temperature-controlled packaging ensures that molecular integrity is preserved from our cleanroom environments to your laboratory bench.
Bulk Procurement and Institutional Accounts
For high-throughput screening, longitudinal animal studies, or multi-center research initiatives, procurement costs can be optimized by establishing a wholesale account. Bulk ordering reduces individual vial packaging overhead and minimizes batch-to-batch analytical variance by supplying entire projects from a single, uniform synthesis lot.
PX1 Research offers reserved lot allocation for research institutions, ensuring that longitudinal studies maintain complete continuity in batch purity, salt form balance, and mass spectra profiles over extended research timelines.
Summary: Balancing Price and Analytical Rigor
Selecting a supplier based strictly on the lowest CJC 1295 DAC price introduces significant experimental risk, including compromised purity, variable peptide content, and potential endotoxin contamination. Securing fully documented, high-purity research materials ensures high experimental reproducibility and accurate quantitative data.
PX1 Research provides USA-manufactured research peptides supported by complete third-party HPLC/MS verification, low endotoxin guarantees, and transparent batch tracking, setting the industry benchmark for laboratory supply.
Frequently Asked Questions
What is the typical CJC 1295 DAC price per vial for research use?
Research-grade CJC-1295 DAC generally ranges from $30 to $70 per vial depending on quantity, purity tier (>98%), and third-party analytical verification included by the supplier.
Why does CJC-1295 DAC cost more than CJC-1295 No DAC?
CJC-1295 DAC requires additional synthetic steps to conjugate the maleimidopropionic acid (MPA) Drug Affinity Complex linker, increasing manufacturing complexity, purification costs, and final chemical yield requirements.
What third-party testing is required to verify CJC-1295 DAC quality?
A comprehensive analysis requires Reverse-Phase High-Performance Liquid Chromatography (RP-HPLC) for purity determination, Electrospray Ionization Mass Spectrometry (ESI-MS) for molecular identity, and LAL assays for endotoxin quantification.
What is the purpose of the Drug Affinity Complex (DAC) in research?
The DAC modification enables the peptide to form a covalent bond with endogenous serum albumin, extending its biological half-life in preclinical models from minutes to several days.
How should CJC-1295 DAC be stored upon delivery?
Lyophilized powder should be stored at -20°C for short-term preservation or -80°C for long-term stability. Once reconstituted in bacteriostatic water, it should be kept refrigerated at 2°C to 8°C.
Are volume discounts available for CJC-1295 DAC procurement?
Yes, PX1 Research provides institutional tier pricing and custom wholesale arrangements for high-volume orders through our dedicated wholesale portal.
What diluent should be used for reconstituting CJC-1295 DAC in laboratory settings?
Sterile bacteriostatic water (0.9% benzyl alcohol) is standard for multi-dose laboratory sampling to maintain sterility and structural stability.
What are the endotoxin limits for PX1 Research peptides?
All PX1 Research compounds are tested to ensure endotoxin levels remain strictly below <0.01 EU/mg, minimizing inflammatory artifacts in cellular and animal models.
Related pages
All products are sold strictly for laboratory and research use only. Not for human or veterinary use, diagnosis, treatment or consumption. Statements have not been evaluated by the FDA.